Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2013; 42: 606-615 Year: 2013
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Dose-response to tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) to patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 318s Year: 2006
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD Source: International Congress 2018 – COPD management Year: 2018
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012